Previous studies have demonstrated that gene editing is feasible in CD34+ cells from patients with hematological disorders such as SCID‐X1 (Genovese et al, 2014) or chronic granulomatous disease (CGD) (De Ravin et al, 2016). The gene discussed is CD34; the disease is chronic granulomatous disease.